Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Jul;100(1):88-97.
doi: 10.3945/ajcn.113.081133. Epub 2014 May 14.

DHA-enriched high-oleic acid canola oil improves lipid profile and lowers predicted cardiovascular disease risk in the canola oil multicenter randomized controlled trial

Affiliations
Randomized Controlled Trial

DHA-enriched high-oleic acid canola oil improves lipid profile and lowers predicted cardiovascular disease risk in the canola oil multicenter randomized controlled trial

Peter J H Jones et al. Am J Clin Nutr. 2014 Jul.

Abstract

Background: It is well recognized that amounts of trans and saturated fats should be minimized in Western diets; however, considerable debate remains regarding optimal amounts of dietary n-9, n-6, and n-3 fatty acids.

Objective: The objective was to examine the effects of varying n-9, n-6, and longer-chain n-3 fatty acid composition on markers of coronary heart disease (CHD) risk.

Design: A randomized, double-blind, 5-period, crossover design was used. Each 4-wk treatment period was separated by 4-wk washout intervals. Volunteers with abdominal obesity consumed each of 5 identical weight-maintaining, fixed-composition diets with one of the following treatment oils (60 g/3000 kcal) in beverages: 1) conventional canola oil (Canola; n-9 rich), 2) high-oleic acid canola oil with docosahexaenoic acid (CanolaDHA; n-9 and n-3 rich), 3) a blend of corn and safflower oil (25:75) (CornSaff; n-6 rich), 4) a blend of flax and safflower oils (60:40) (FlaxSaff; n-6 and short-chain n-3 rich), or 5) high-oleic acid canola oil (CanolaOleic; highest in n-9).

Results: One hundred thirty individuals completed the trial. At endpoint, total cholesterol (TC) was lowest after the FlaxSaff phase (P < 0.05 compared with Canola and CanolaDHA) and highest after the CanolaDHA phase (P < 0.05 compared with CornSaff, FlaxSaff, and CanolaOleic). Low-density lipoprotein (LDL) cholesterol and high-density lipoprotein (HDL) cholesterol were highest, and triglycerides were lowest, after CanolaDHA (P < 0.05 compared with the other diets). All diets decreased TC and LDL cholesterol from baseline to treatment endpoint (P < 0.05). CanolaDHA was the only diet that increased HDL cholesterol from baseline (3.5 ± 1.8%; P < 0.05) and produced the greatest reduction in triglycerides (-20.7 ± 3.8%; P < 0.001) and in systolic blood pressure (-3.3 ± 0.8%; P < 0.001) compared with the other diets (P < 0.05). Percentage reductions in Framingham 10-y CHD risk scores (FRS) from baseline were greatest after CanolaDHA (-19.0 ± 3.1%; P < 0.001) than after other treatments (P < 0.05).

Conclusion: Consumption of CanolaDHA, a novel DHA-rich canola oil, improves HDL cholesterol, triglycerides, and blood pressure, thereby reducing FRS compared with other oils varying in unsaturated fatty acid composition. This trial was registered at www.clinicaltrials.gov as NCT01351012.

PubMed Disclaimer

Figures

FIGURE 1.
FIGURE 1.
Flow of participants throughout the study.
FIGURE 2.
FIGURE 2.
Percentage change in serum lipids from treatment-specific baseline in response to 5 treatment diets. Percentage change was calculated from the baseline value of each dietary phase. The bars represent least-squares means for n = 130. The error bars reflect SEMs. The treatment effect was analyzed by using a mixed model with repeated measures adjusted by Tukey's test for multiple comparisions. Mean values with different lowercase letters are significantly different, P < 0.05. Canola, conventional canola oil (Richardson Oilseed Ltd); CanolaDHA, high–oleic acid canola oil (Richardson Oilseed Ltd) with DHA (Martek Biosciences Corporation); CanolaOleic, high–oleic acid canola oil; CornSaff, corn oil (Loblaws Inc) and safflower oil (Loblaws Inc) blend; FlaxSaff, flax oil (Shape Foods Inc) and safflower oil blend; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; TC, total cholesterol; TG, triglycerides.
FIGURE 3.
FIGURE 3.
Comparison of percentage changes in Framingham 10-y coronary heart disease risk scores after 5 treatment diets. Percentage changes were calculated from baseline Framingham 10-y coronary heart disease risk scores of each dietary phase. The bars reflect the least-squares means (n = 130). The error bars reflect SEMs. The treatment effects were analyzed by using a mixed model with repeated measures adjusted by Tukey's test. Mean values with different lowercase letters are significantly different, P < 0.05. Canola, conventional canola oil (Richardson Oilseed Ltd); CanolaDHA, high–oleic acid canola oil (Richardson Oilseed Ltd) with DHA (Martek Biosciences Corporation); CanolaOleic, high–oleic acid canola oil; CornSaff, corn oil (Loblaws Inc) and safflower oil (Loblaws Inc) blend; FlaxSaff, flax oil (Shape Foods Inc) and safflower oil blend.

Similar articles

Cited by

References

    1. Chowdhury R, Warnakula S, Kunutsor S, Crowe F, Ward HA, Johnson L, Franco OH, Butterworth AS, Forouhi NG, Thompson SG, et al. Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. Ann Intern Med 2014;160:398–406. - PubMed
    1. Hibbeln JR, Nieminen LR, Blasbalg TL, Riggs JA, Lands WE. Healthy intakes of n−3 and n−6 fatty acids: estimations considering worldwide diversity. Am J Clin Nutr 2006;83:1483S–93S. - PubMed
    1. Bergouignan A, Momken I, Schoeller DA, Simon C, Blanc S. Metabolic fate of saturated and monounsaturated dietary fats: the Mediterranean diet revisited from epidemiological evidence to cellular mechanisms. Prog Lipid Res 2009;48:128–47. - PubMed
    1. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002;106:2747–57. - PubMed
    1. O'Flaherty M, Buchan I, Capewell S. Contributions of treatment and lifestyle to declining CVD mortality: why have CVD mortality rates declined so much since the 1960s? Heart 2013;99:159–62. - PubMed

Publication types

MeSH terms

Associated data